Form 990 for tax year 2023

Totals

Total revenue

$15,132,739

Total expenses

$21,845,674

Contributions and grants received

$15,104,824

Grants paid

$2,483,399

Program service revenue

$0

Investment income

$18,333

Other revenue

$9,582

Total assets, end of year

$48,982,028

Total liabilities, end of year

$10,026,647

Net assets or fund balances, end of year

$38,955,381

Program services expenses (Part IX)

$11,268,889

Management and general expenses

$10,148,387

Fundraising expenses

$428,398

Program service expenses (Part III)

$11,268,889

Program services were 51.6% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2023

• Withheld by Nonprofiteer: this text may name a private individual.

  Expenses $8,738,224 · Grants $2,412,163

• Withheld by Nonprofiteer: this text may name a private individual.

  Expenses $799,972

• Withheld by Nonprofiteer: this text may name a private individual.

  Expenses $1,692,603 · Grants $71,236

• OTHER: AS PART OF THEIR INAUGURAL GRANT CYCLE, THE CONRAD PREBYS FOUNDATION FUNDED THE INSTITUTES RESEARCH WORK IN BOTH CORONARY ARTERY DISEASE AND SARS-COV-2. HEART DISEASE IS THE LEADING CAUSE OF DEATH IN THE US AND CORONARY ARTERY DISEASE (CAD) IS THE MOST COMMON TYPE OF HEART DISEASE, KILLING ~366,000 PEOPLE ANNUALLY IN THE US. ABOUT 6.7% (18.2 MILLION) US ADULTS HAVE CAD AND ~20% OF DEATHS FROM CAD OCCUR BEFORE AGE 65. A LIST OF GENETIC FACTORS LINKED TO CAD HAS BEEN FOUND OVER THE LAST FEW DECADES. BUT THEY ONLY EXPLAIN A SMALL PORTION OF THE HERITABILITY IN CAD. TO BETTER UNDERSTAND THE GENETICS AND ETIOLOGY OF CAD AT GENOMIC LEVEL, MORE RARE GENETIC VARIANTS NEED TO BE INVESTIGATED. LED BY WEIZHONG LI, THIS PROJECT, ANALYZED THE WHOLE GENOME DEEP SEQUENCE DATA OF A LARGE COHORT OF ~1000 CAD PATIENTS. USING THE CLOUD-BASED GENOME ANALYSIS PIPELINE, HUNDREDS OF TERABYTES OF SEQUENCE DATA WERE PROCESSED AND MILLIONS OF VARIOUS TYPES OF GENETIC VARIANTS WERE IDENTIFIED. A LIST OF VARIANTS ARE FOUND TO BE ASSOCIATED WITH CAD AND THE EXTENT OF DISEASE IN CAD. BY USING MACHINE LEARNING APPROACHES, WE BUILT VERY ACCURATE PREDICTIVE MODELS FOR THE PREDICTION OF CAD RISKS AND DISEASE SEVERITY. EARLY WARNING SYSTEM FOR SARS-COV-2 IMMUNE ESCAPE PROJECT. NEUTRALIZING ANTIBODIES ELICITED AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) SPIKE PROTEIN IS WIDELY ACCEPTED AS THE MAIN CORRELATE OF PROTECTION. TO BETTER UNDERSTAND THE ROLE OF ANTIBODIES IN NEUTRALIZATION AND PROTECTION, JCVI, LED BY RICHARD SCHEUERMANN, PHD, AND GENE TAN, PHD, IS CONSTRUCTING A PANEL OF CHIMERIC PSEUDOVIRUSES (BASED ON THE VESICULAR STOMATITIS VIRUS PLATFORM) THAT WE HYPOTHESIZE CAN REVEAL THE IMMUNOLOGICAL DOMINANT AND SUBDOMINANT ANTIGENIC REGIONS OF THE SPIKE PROTEIN. NOTABLY, OUR APPROACH CAN IDENTIFY SUBDOMINANT REGIONS WITHIN THE SPIKE THAT ARE HIGHLY CONSERVED EVEN AMONGST SARS-COV-2 VARIANTS OF CONCERN (VOCS). COVID19 CONTINUES TO IMPACT GLOBAL HEALTH, HIGHLIGHTING THE NEED TO DEVELOP NOVEL THERAPEUTICS. MARCELO FREIRE, PHD, AND HIS LABORATORY DISCOVERED THAT SALIVA IS A BIOFLUID IMPORTANT FOR MEASURING THE VIRUS BUT ALSO THE IMMUNE RESPONSE PRESENTING DIVERSE IMMUNE CELL POPULATIONS. WHITIN SALIVA, WE FIND VARIOUS ANTIVIRAL, ANTI-INFLAMMATORY AND ANTI-BACTERIAL FUNCTIONS. DIFFERENT FROM BLOOD, SALIVARY IMMUNE CELLS ARE IN DIRECT CONTACT WITH THE LIVE VIRUS. IN THIS PROPOSAL WE INVESTIGATED (I) THE COMPOSITION OF ANTIVIRAL IMMUNE CELLS, (II) THE PROTEIN SEQUENCE OF ANTIVIRAL MOLECULES DERIVED FROM INNATE IMMUNE CELLS, AND (III) THEIR MECHANISM OF ACTION. THE FREIRE LAB HAVE SUCCESSFULLY COLLECTED SAMPLES FROM COVID-19 AND HEALTHY CONTROL SAMPLES AND INITIATED SEQUENCING OF SALIVA CELLS IN HEALTH AND IN COVID-19. IN ADDITION, WE ALSO RECRUITED SAMPLES LONGITUDINALLY AT JCVI TO EVALUATE HEALTHY VERSUS DISEASE. TO DATE, WE COMPLETED IMMUNOGLOBULIN IMMUNOASSAYS OF ALL OUR SAMPLES INCLUDING INVESTIGATIONS TO CUSTOM ELISA ASSAYS FOR SARS-COV-2 ANTIGENS (RBD, S1, S2, NP PROTEINS). WE HAVE IDENTIFIED THAT SALIVARY IMMUNOGLOBULIN IGA AS HIGHLY SIGNIFICANT COMPARED TO BLOOD PLASMA LEVELS. SEVERAL MARKERS FROM IGG AND IGA RESPONSES WERE FOUND IN SALIVA AS WELL AS PLASMA. SIMPLE LINEAR REGRESSION MODEL VERIFIED SIGNIFICANT CORRELATIONS BETWEEN SALIVA AND PLASMA ANTIBODY RESPONSES, SPECIFICALLY FOR THE IGA (P=0.001), IGG (P=0.037), AND IGM (P=0.0054) SPECIFIC TO THE SARS-COV-2 RECEPTOR BINDING SITE (RBD). THESE ARE ANTIVIRAL MOLECULES THAT HAVE POTENTIAL TO BLOCK VIRAL ACTIVITY. TO TEST THIS FURTHER FROM OUR ASSAYS, JCVI PERFORMED A NEUTRALIZATION ASSAY AND COMPARATIVE ANALYSIS TO UNDERSTAND IF THESE MOLECULES HAVE A FUNCTIONAL RESPONSE. DESPITE THAT SALIVA CONTAINED ROBUST IGA RESPONSE TO THE SARS-COV-2, WHICH WAS EVEN HIGHER THAN PLASMA, MOST OF SALIVA SAMPLES DEMONSTRATED LEVEL OF NEUTRALIZATION OF VESICULAR STOMATITIS VIRUS (VSV) PSEUDOVIRUSES BEARING S OF SARS-COV-2 (RVSV-GFPG*SPIKE). IT WAS CONTRASTED WITH THAT THE PLASMA DISPLAYED A SIGNIFICANT LEVEL OF NEUTRALIZING ACTIVITY EVEN FROM HEALTHY INDIVIDUALS. THESE RESULTS SUGGEST THAT THE ORAL MUCOSAL IMMUNE COMPONENTS COOPERATE WITH SYSTEMIC IMMUNE RESPONSE IN RESPONSE TO THE SARS-COV-2 INFECTION. SALIVA AND PLASMA SAMPLES CONTAINED SIGNIFICANTLY HIGHER LEVELS OF SARS-COV-2 SPECIFIC ANTIBODIES THAN HEALTHY AND WE DISCOVERED MULTIPLE PEPTIDES PRESENT A ROLE AGAINST VIRAL PARTICLES. ULTIMATELY, THIS PROJECT AIMS TO MAP THE SALIVARY MOLECULAR CONTENT WHEN EXPOSED TO THE VIRUS. WE AIM PROVIDE TO THE SCIENTIFIC COMMUNITY A NEW LAYER OF IMMUNE RESPONSE COMPOSITION AND FUNCTION RELATED TO MUCOSAL LINING WHEN FACING VIRAL ATTACK. THIS WILL THEN GUIDE NEW CLINICAL APPROACHES WITH THE FORMATION OF THE THERAPEUTICS THAT EMULATE HOW AND WHY THE MUCOSAL TISSUES KEEP DISEASE IN CHECK. SANJAY VASHEE, PHD, COLLABORATING WITH INVESTIGATORS AT THE UNIVERSITY OF MARYLAND TO USE SYNTHETIC GENOMICS TO DEVELOP A SARS-COV-2 INFECTIOUS CLONE. THEY ARE PAIRING THIS WITH A RAPID, MODULAR REVERSE GENETIC SYSTEM TO ASSESS GENOMIC VARIANTS IDENTIFIED IN THE WEALTH OF GLOBAL SEQUENCING DATA, DEVELOP AND TEST VACCINE CANDIDATES, AND GENERATE NEEDED REAGENTS, INCLUDING FLUORESCENT AND TAGGED VIRUS STRAINS. MARCELO FREIRE, PHD, IS LEADING EFFORTS IN THE DEVELOPMENT OF A SALIVARY SEROLOGICAL AND IMMUNE TESTING. MONITORING SALIVA IMMUNITY PROVIDES NON-INVASIVE MOLECULAR INFORMATION, ESSENTIAL FOR DIAGNOSTICS, AND RESPONSE TO THERAPY DURING THE PANDEMIC. HIS LABORATORY IS COMPARING COVID-19 PATIENTS' BLOOD AND SALIVARY IMMUNOGLOBULINS LEVELS TO FIND BETTER WAYS TO EVALUATE IMMUNE RESPONSE TO SARS-COV-2.

  Expenses $38,090

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here. A text marked withheld matched a screen for wording that may name a private individual, such as an honorific or "in memory of". Most of what it withholds names no one; it is withheld so that what does is never shown.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• UNIVERSITY OF CALIFORNIA SAN DIEGO

  $628,139

  RESEARCH SUBGRANT

• CASE WESTERN RESERVE UNIVERSITY

  $409,716

  RESEARCH SUBGRANT

• VANDERBILT UNIVERSITY

  $302,028

  RESEARCH SUBGRANT

• RHODE ISLAND HOSPITAL

  $256,018

  RESEARCH SUBGRANT

• DUKE UNIVERSITY

  $201,837

  RESEARCH SUBGRANT

• UNIVERSITY OF MARYLAND

  $200,549

  RESEARCH SUBGRANT

• COLORADO STATE UNIVERSITY

  $147,113

  RESEARCH SUBGRANT

• NORTHWESTERN UNIVERSITY

  $87,777

  RESEARCH SUBGRANT

• LELAND STANFORD JR UNIVERSITY

  $79,880

  RESEARCH SUBGRANT

• UNIVERSITY OF ALABAMA BIRMINGHAM

  $46,654

  RESEARCH SUBGRANT

The 10 largest by cash amount. The API serves every itemized grant.

Provenance

Return type

form_990

Tax year

2023

Filed

5 November 2024

IRS schema version

2023v5.1

Source object

202443109349303919

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.